MetaCap

Pelthos Therapeutics Inc. (PTHS)

NYSE: PTHSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.38-0.61 (-8.73%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PTHS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$25.08M
EPS (TTM)
-$23.86
52-week range
6.02 – 31.62
Day range
6.38 – 7.21
Volume / Avg
63.96K / 54.38K
Beta
—

52-week range

$6.02$31.62

PTHS stock today

Shares of Pelthos Therapeutics (PTHS) finished lower on Nov 20 at $6.38, a drop of 8.73% or $0.61 per share, versus the S&P 500's 3.70% decline. Shares are 79.8% below their 52-week high of $31.62, set on Dec 31, 2025 and 6.0% above the 52-week low of $6.02, near the bottom of the past year's range. PTHS is down 79.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 74.9%.

Pelthos Therapeutics has posted a net loss over the last twelve months (EPS of -$23.86), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Pelthos Therapeutics

Company profile

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Scott M. Plesha
Headquarters
Durham, NC
Employees
92
IPO year
2024

Financial highlights

Full financials

In fiscal 2025, Pelthos Therapeutics generated $16.8 million in revenue, up 0.0% from fiscal 2024. Pelthos Therapeutics reported a net loss of $43.3 million, compared with a loss of $8.0 million a year earlier. Gross margin was 76.3% and operating margin -193.1%.

Pelthos Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue$16.80M$0——
Growth————
Net income$-43.32M$-7.96M$-7.38M$-2.46M
EPS (diluted)$-23.04$-14.27$-5.78—

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$53.14+732.92%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $45.00High $64.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-2.04 vs $-2.83
Surprise
+27.92%

PTHS news

All PTHS news

Pelthos Therapeutics peers

Health Care sector
PTHS peer companies
CompanyPrice% ChgMarket capCompare
INMBINmune Bio Inc.0.827-7.50%$25.60Mvs PTHS
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs PTHS
LONALeonaBio Inc.2.02-17.89%$26.41Mvs PTHS
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs PTHS
MGXMetagenomi Therapeutics Inc.0.565-7.95%$21.36Mvs PTHS
CVMCel-Sci Corporation1.21-17.69%$21.28Mvs PTHS
EVAXEvaxion A/S ADR2.25+10.84%$20.75Mvs PTHS
KLRSKalaris Therapeutics Inc.1.28-5.19%$30.47Mvs PTHS

Indexes, lists and sector

Pelthos Therapeutics stock FAQ

What is Pelthos Therapeutics's stock price today?

PTHS last traded at $6.38 as of Nov 20, 4:00 PM EST, down 8.73% on the day. Prices are delayed at least 15 minutes.

Does Pelthos Therapeutics pay a dividend?

No. Pelthos Therapeutics does not currently pay a regular cash dividend.

Who is Pelthos Therapeutics's CEO?

Mr. Scott M. Plesha is the chief executive officer of Pelthos Therapeutics Inc., which has about 92 employees.

Has PTHS ever split its stock?

Yes. The most recent PTHS stock split was a 1-for-10 split on Jul 2, 2025.

What is the PTHS 52-week high?

The 52-week high for PTHS is $31.62 and the 52-week low is $6.02. The stock is currently 79.8% below its high.

Compare PTHS